Application of invtravenous lidocaine in patients undergoing hysteroscpy surgery

Application of intravenous lidocaine in patients undergoing hysteroscpy surgery under Narcotrend monitoring

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016857

Enrollment

Unknown

Registered

2018-06-28

Start date

2018-07-01

Completion date

Unknown

Last updated

2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine adhesions

Interventions

Group L:Lidocaine 1.5 mg/kg intravenously immediately before induction of anesthesia, followed by continuous infusion to the end of surgery at 2 mg/kg/h

Control group:Normal saline 1.5 mg/kg intravenously immediately before induction of anesthesia, followed by continuous infusion to the end of surgery at 2 mg/kg/h

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) ASA I-II; (2) Patients scheduled to undergo hysteroscopic surgery.

Exclusion criteria

Exclusion criteria: (1) Lidocaine allergic patients; (2) Abnormal liver and kidney function; (3) Chronic pain, long-term use of opioids or non-steroidal drugs; (4) Patients with atrioventricular block.

Design outcomes

Primary

Measure	Time frame
Total Propofol;Total remifentanil;Visual analog score;Throat pain incidence;	—

Countries

China

Contacts

Public ContactZhan Liying

Renmin Hospital of Wuhan University

2582062108@qq.com+86 15327408448

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026